The Impact of Longitudinal Substance Use Patterns on the Risk of Opioid Agonist Therapy Discontinuation: A Repeated Measures Latent Class Analysis

Overview

Journal Int J Ment Health Addict

Date 2024 Dec 26

PMID 39722780

Authors

Zishan Cui

Mohammad Karamouzian

Michael Law

Kanna Hayashi

M-J Milloy

Thomas Kerr

Affiliations

Soon will be listed here.

Abstract

Supplementary Information: The online version contains supplementary material available at 10.1007/s11469-023-01098-8.

References

Hurd Y, Yoon M, Manini A, Hernandez S, Olmedo R, Ostman M . Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage. Neurotherapeutics. 2015; 12(4):807-15. PMC: 4604178. DOI: 10.1007/s13311-015-0373-7. View

Darke S . Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998; 51(3):253-63; discussion 267-8. DOI: 10.1016/s0376-8716(98)00028-3. View

Buxton J, Dove N . The burden and management of crystal meth use. CMAJ. 2008; 178(12):1537-9. PMC: 2396355. DOI: 10.1503/cmaj.071234. View

Banks D, Hershberger A, Pemberton T, Clifton R, Aalsma M, Zapolski T . Poly-use of cannabis and other substances among juvenile-justice involved youth: variations in psychological and substance-related problems by typology. Am J Drug Alcohol Abuse. 2019; 45(3):313-322. PMC: 6450756. DOI: 10.1080/00952990.2018.1558450. View

Zhu Y, Evans E, Mooney L, Saxon A, Kelleghan A, Yoo C . Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial. J Neuroimmune Pharmacol. 2018; 13(4):488-497. PMC: 6224303. DOI: 10.1007/s11481-018-9801-x. View

Bahji A, Cheng B, Gray S, Stuart H . Reduction in mortality risk with opioid agonist therapy: a systematic review and meta-analysis. Acta Psychiatr Scand. 2019; 140(4):313-339. DOI: 10.1111/acps.13088. View

The Lancet Public Health . A public health approach to Canada's opioid crisis. Lancet Public Health. 2018; 3(5):e204. DOI: 10.1016/S2468-2667(18)30078-1. View

Scavone J, Sterling R, Weinstein S, Van Bockstaele E . Impact of cannabis use during stabilization on methadone maintenance treatment. Am J Addict. 2013; 22(4):344-51. PMC: 4717827. DOI: 10.1111/j.1521-0391.2013.12044.x. View

Jones J, Mogali S, Comer S . Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012; 125(1-2):8-18. PMC: 3454351. DOI: 10.1016/j.drugalcdep.2012.07.004. View

10.

Deck D, Carlson M . Retention in publicly funded methadone maintenance treatment in two Western States. J Behav Health Serv Res. 2005; 32(1):43-60. DOI: 10.1007/BF02287327. View

11.

Bruneau J, Ahamad K, Goyer M, Poulin G, Selby P, Fischer B . Management of opioid use disorders: a national clinical practice guideline. CMAJ. 2018; 190(9):E247-E257. PMC: 5837873. DOI: 10.1503/cmaj.170958. View

12.

Priest K, Gorfinkel L, Klimas J, Jones A, Fairbairn N, McCarty D . Comparing Canadian and United States opioid agonist therapy policies. Int J Drug Policy. 2019; 74:257-265. PMC: 6689455. DOI: 10.1016/j.drugpo.2019.01.020. View

13.

MacDougall L, Smolina K, Otterstatter M, Zhao B, Chong M, Godfrey D . Development and characteristics of the Provincial Overdose Cohort in British Columbia, Canada. PLoS One. 2019; 14(1):e0210129. PMC: 6328267. DOI: 10.1371/journal.pone.0210129. View

14.

Banta-Green C, Maynard C, Koepsell T, Wells E, Donovan D . Retention in methadone maintenance drug treatment for prescription-type opioid primary users compared to heroin users. Addiction. 2009; 104(5):775-83. DOI: 10.1111/j.1360-0443.2009.02538.x. View

15.

Zhang Z, Friedmann P, Gerstein D . Does retention matter? Treatment duration and improvement in drug use. Addiction. 2003; 98(5):673-84. DOI: 10.1046/j.1360-0443.2003.00354.x. View

16.

Karamouzian M, Buxton J, Hategeka C, Nosova E, Hayashi K, Milloy M . Shifts in substance use patterns among a cohort of people who use opioids after delisting of OxyContin in BC, Canada: An interrupted time series study. Int J Drug Policy. 2022; 109:103852. PMC: 9885984. DOI: 10.1016/j.drugpo.2022.103852. View

17.

Karamouzian M, Pilarinos A, Hayashi K, Buxton J, Kerr T . Latent patterns of polysubstance use among people who use opioids: A systematic review. Int J Drug Policy. 2022; 102:103584. DOI: 10.1016/j.drugpo.2022.103584. View

18.

Kennedy A, Wessel C, Levine R, Downer K, Raymond M, Osakue D . Factors Associated with Long-Term Retention in Buprenorphine-Based Addiction Treatment Programs: a Systematic Review. J Gen Intern Med. 2021; 37(2):332-340. PMC: 8810983. DOI: 10.1007/s11606-020-06448-z. View

19.

Crummy E, ONeal T, Baskin B, Ferguson S . One Is Not Enough: Understanding and Modeling Polysubstance Use. Front Neurosci. 2020; 14:569. PMC: 7309369. DOI: 10.3389/fnins.2020.00569. View

20.

Wood E, Hogg R, Bonner S, Kerr T, Li K, Palepu A . Staging for antiretroviral therapy among HIV-infected drug users. JAMA. 2004; 292(10):1175-7. DOI: 10.1001/jama.292.10.1175-b. View